What’s New

Latest News

Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
First Report Managed Care
Research Review
Colon Cancer Mortality Declines Reverse After 2013
05/29/2026
Jessica Garlewicz
Data indicate that while overall mortality from colorectal cancer has declined over the past 30 years, the rate increased from 2013 to 2023 and may continue to rise through 2040.
Data indicate that while overall mortality from colorectal cancer has declined over the past 30 years, the rate increased from 2013 to 2023 and may continue to rise through 2040.
Data indicate that while overall...
05/29/2026
Gastroenterology
Gastroenterology
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
FDA Approval
FDA Approves Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
05/28/2026
Stephanie Holland
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase...
05/28/2026
Oncology
Oncology
a woman scrolls on her phone while laying in bed
News
US Study Finds No Link Between AI Use and Depression
05/28/2026
Maria Mantas
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation...
05/28/2026
Psych Congress Network
Psych Congress Network
News
Busulfan Injections Recalled Due to Failed Impurities/Degradation Specifications
05/28/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug...
05/28/2026
Pharmacy Learning Network
Pharmacy Learning Network
Ninth Brain Logo
News
Ninth Brain and MeduPros Partner to Elevate Critical Care Transport Education
05/27/2026
New collaboration delivers high-impact, real-world clinical training directly within the Ninth Brain platform.
New collaboration delivers high-impact, real-world clinical training directly within the Ninth Brain platform.
New collaboration delivers...
05/27/2026
EMSWorld
EMSWorld

Latest Research

Vascular Disease Management logo
Vascular Disease Management
Tackling the Calcium Challenge: Managing Recoil, Rupture, and Occlusion
Vol. 23, Issue 4, Issue May 2026
April/May 2026 cover
The Dermatologist
Evolution of Aesthetics in Dermatology
Vol. 34, Issue 3, Issue May 2026

HMP Global Learning Network

Featured Interviews

CTP News Desk Image
Viewpoint
Operational Observations in a New CTP Regulatory Environment
05/08/2026
Nikki Johnston; Kati Kaushal, DNP, FNP-C, CWS
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these...
05/08/2026
Wounds
Advances in Charcot Neuroarthropathy Surgical Techniques Video
Videos
Advances in Charcot Neuroarthropathy Surgical Techniques Video
05/01/2026
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Kyle Lawton, DPM
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight...
05/01/2026
Podiatry Today
Jonathan Friedberg, MD
Videos
Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma
04/30/2026
Jonathan W. Friedberg, MD, MMSc
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc,...
04/30/2026
Oncology
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
Rachid Baz, MD
Videos
BCMA-Targeted Bispecifics and CAR-T in Frontline Multiple Myeloma
03/31/2026
Rachid Baz, MD
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the...
03/31/2026
Oncology
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Pediatric Video Tutorial: Communicating With Deaf Patients Part 2
Videos
Pediatric Video Tutorial: Communicating With Deaf Patients Part 2
03/02/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
With invaluable insights from a certified interpreter for the deaf, part two of this four-part series rapidly reviews what medical professionals really need to know, and what their deaf patients wish their caregivers knew.
With invaluable insights from a certified interpreter for the deaf, part two of this four-part series rapidly reviews what medical professionals really need to know, and what their deaf patients wish their caregivers knew.
With invaluable insights from a...
03/02/2026
EMSWorld
Allen Kaplan
RESEARCH INSIGHTS
Diagnostic Challenges and Clinical Pitfalls in HAE
03/02/2026
Allen P. Kaplan, MD
Dr Allen Kaplan reviews common diagnostic pitfalls in hereditary angioedema, including misinterpretation of complement testing, confusion with histaminergic angioedema, and challenges in identifying HAE with normal C1 inhibitor.
Dr Allen Kaplan reviews common diagnostic pitfalls in hereditary angioedema, including misinterpretation of complement testing, confusion with histaminergic angioedema, and challenges in identifying HAE with normal C1 inhibitor.
Dr Allen Kaplan reviews common...
03/02/2026
Allergy & Immunology
Zeymer title card
Author Interview
Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization: An Interview With Uwe Zeymer, MD
02/27/2026
Uwe Zeymer, MD
Dr Uwe Zeymer shares background and insights on his article, "Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization."
Dr Uwe Zeymer shares background and insights on his article, "Hospital Outcomes of Patients With Acute Myocardial Infarction-Related Cardiogenic Shock With and Without Revascularization."
Dr Uwe Zeymer shares background...
02/27/2026
Journal of Invasive Cardiology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use